TriangleDISEASE & TREATMENT SETTING
recurrent Childhood Ependymoma
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
Treatment of Recurrent Childhood Ependymoma
Broader topic: Childhood Ependymoma
- Source population
- pediatric
- Disease extent
- recurrent
- Treatment line
- Not part of this definition
- Stage
- Not part of this definition
- Resectability
- Not part of this definition
Biomarkers, prior therapy and derivation
- molecular
- prior therapy
- class
- prior therapy
- status
- stated
- derivation status
- source-attested
- derivation note
- Scoped from an NCI treatment-summary heading. NCI PDQ is an evidence summary, not a practice guideline, and only the dimensions the heading states are part of this definition.
- source wording
- Treatment of Recurrent Childhood Ependymoma
Study evidence for this setting
Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric
Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell C
Source relationships and population-mapping limitations
- bindings
- mappings
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice